Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects...
LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial
Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by...
BEAM-302 Trial Shows Compelling Data for AATD Treatment
Beam’s Phase 1/2 readout for BEAM-302 in severe alpha-1 antitrypsin deficiency (AATD) delivered clean, quantitative signals: at the 60...
C4 Therapeutics Begins Phase 1b Trial for Multiple Myeloma
C4 Therapeutics has dosed the first patient in a Phase 1b study assessing cemsidomide plus dexamethasone in combination with...
The Wearable Gap: Why Sensors Are Outrunning the Trials That Use Them
Wearables are generating physiological data at a scale clinical trials have never seen before. But a March 2026 review...
Aclaris Announces Phase 2a Trial Results for ATI-2138 at AAD
Aclaris will present new results from its open-label Phase 2a study of ATI-2138, an oral covalent inhibitor of ITK...
Wallaby Treats First U.S. Patient in PIANO Aneurysm Trial
More than 20,000 patients have been treated outside the United States with the p48 and p64 MW HPC flow...
Largest Lung Nodule Study: A Breakthrough for Diagnosis
In a retrospective pooled analysis of 1,100 patients with 4–30 mm noncalcified pulmonary nodules, the Nodify CDT blood-based autoantibody...
Patient Dosing Begins in Promising Phase II LSALT Peptide Trial
No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for...
Hutchmed Starts Phase III Trial for B-Cell Lymphoma in China
A randomized, double-blind Phase II study of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL reportedly improved ORR, CRR, PFS, and...